CNBX Cannabics Pharmaceuticals has an agreement with Purisys, a leading Active Pharmaceutical Iingredient manufacturer, to use its API in Phase I/II (a) clinical studies that it is planning to launch in 2022.
So this year will be quite bullish for CNBX
Cannabics Pharmaceuticals is a U.S. public company and a global leader in the development of cancer related...
